Picture of Verrica Pharmaceuticals logo

VRCA Verrica Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m+44.42%
3m-14.25%
6m+52.72%
1yr-61.87%
Volume Change (%)
10d/3m-15.29%
Price vs... (%)
52w High-67.15%
50d MA+28.22%
200d MA-22.07%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-54.24%
Return on Equity-65.63%
Operating Margin-278.78%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Verrica Pharmaceuticals EPS forecast chart

Profile Summary

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. The Company's lead product candidate, VP-102, is a drug-device combination of its topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. It is developing VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts. It also intends to develop its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot. It also intends to develop its third product candidate, LTX-315, for the treatment of dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
July 3rd, 2013
Public Since
June 15th, 2018
No. of Shareholders
21
No. of Employees
38
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
41,094,053

VRCA Share Price Performance

Upcoming Events for VRCA

Q4 2022 Verrica Pharmaceuticals Inc Earnings Release

Q1 2023 Verrica Pharmaceuticals Inc Earnings Release

Similar to VRCA

Picture of ADMA Biologics logo

ADMA Biologics

us flag iconNASDAQ Global Market

Picture of Alimera Sciences logo

Alimera Sciences

us flag iconNASDAQ Global Market

Picture of ANI Pharmaceuticals logo

ANI Pharmaceuticals

us flag iconNASDAQ Global Market

Picture of Aptorum logo

Aptorum

us flag iconNASDAQ Global Market

Picture of Aquestive Therapeutics logo

Aquestive Therapeutics

us flag iconNASDAQ Global Market

FAQ

Or unlock with your email

Or unlock with your email